Wechselwirkungen · Janumet
Janumet 50 mg/850 mg film-coated tablets Janumet 50 mg/1 000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-119370 · Präparat HOS-094931
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8. In patients with normal renal function, metabolism, including via CYP3A4, plays only a small role in the clearance of sitagliptin. Metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD). For this reason, it is possible that potent CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the pharmacokinetics of sitagliptin in patients with severe renal impairment or ESRD. The effects of potent CYP3A4 inhibitors in the setting of renal impairment have not been assessed in a clinical study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-10T16:51:00Z · SHA-256 7ab5484fea0dbb19060d54dea7052ed288c9ae1559061c17e0fa301f89920bd6 · Passage aba4fcf33ea6e74cce4fecc93069609f9d98326d0842e3324ccaed7e87f159d7 · Zeichen 2863–3636 im Abschnitt